Evercore ISI Boosts Vertex Pharmaceuticals Price Target to $530 Driven by Povetacicept Prospects
Evercore ISI has raised its price target for Vertex Pharmaceuticals to $530 from $475, maintaining an Outperform rating based on the promising commercial potential of povetacicept and confidence in the company's pipeline. Other analysts have also upgraded their outlooks, highlighting favorable clinical data and market dynamics related to Vertex's k…